Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01753479 · ClinicalTrials.gov registry record · NA

Spectroscopy From Duodenum

A NA study of Pancreatic Adenocarcinoma, sponsored by Olympus Corporation.

Completed
Registry status
NA
Development phase
445
Enrollment target
4
Study locations

NCT01753479 is a NA study of Pancreatic Adenocarcinoma that has completed, run by Olympus Corporation. The registered enrollment target is 445 participants, below the 99,458-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01753479, a NA study of Pancreatic Adenocarcinoma, has completed, sponsored by Olympus Corporation.

COMPLETED
Registry status
NA
Development phase
445 participants
Enrollment target
4
Study locations

Study Summary

Purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.

Conditions Studied

Interventions

  • OTHER Spectroscopy device

Study Locations (4)

Florida

  • Mayo Clinic Florida - Jacksonville

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Brussels Capital

  • Hôpital Erasme - Brussels

Lazio

  • Università Cattolica del Sacro Cuore - Rome

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2013-01
Est. Completion 2016-06-30
Phase NA

Sponsor

Olympus Corporation

2 total trials

What the Registry Record Tells You About NCT01753479

The ClinicalTrials.gov registry entry for NCT01753479 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,458-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Olympus Corporation, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Spectroscopy device is the first listed.

NCT01753479 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Texas, Brussels Capital.

Frequently Asked Questions

What is clinical trial NCT01753479 about?

NCT01753479 is a clinical study titled "Spectroscopy From Duodenum". Purpose of this study is to understand the clinical feasibility of duodenal spectroscopy to adenocarcinoma patients.

What is the current status of trial NCT01753479?

This trial is currently completed. It is a NA study. The enrollment target is 445 participants. The study started on 2013-01. Estimated completion is 2016-06-30.

What conditions does trial NCT01753479 study?

This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT01753479?

The interventions under investigation include: Spectroscopy device (OTHER).

Who is sponsoring clinical trial NCT01753479?

This trial is sponsored by Olympus Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01753479 being conducted?

This trial has 4 study locations across Florida, Texas, Brussels Capital, Lazio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.